Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy aloneIn the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefitResults reinforce two years of Verzenio plus endocrine therapy as the standard of care in HR+, HER2-, node-positive, early breast cancer at a high risk of recu ...

这是一项多中心、随机、双盲、安慰剂对照临床试验，纳入了318例接受过标准治疗的IgAN成人患者， 泰它西普的使用剂量为240mg，皮下注射，每周1次。A阶段分析结果显示：与对照组相比，泰它西普组 患者在治疗39周时的24小时尿蛋白肌酐比值(UPCR)降低了55%(P<0.0001)，且表现出良好的耐受性和安 全性。详细数据将在国际重大学术会议上公布。 荣昌生物(09995)发布公告，公司自主研发的全球首创BLyS/APRIL双靶点融合蛋白创新药泰它西普(商品 名：泰爱)用于治疗IgA肾病(IgAN)的中国III期临床研究，达到A阶段的主要研究终点。集团将尽快向中 国国家药品监督管理局(NMPA)药品审评中心(CDE)递交上市申请(BLA)。 研究表明，B淋巴细胞刺激因子(BLyS)和增殖诱导配体(APRIL)是促进Gd-IgA1及其抗体产生的重要细胞 因子。泰它西普是由公司自主研发的重组BLyS/APRIL双靶点融合蛋白，通过同时抑制BLyS和APRIL与 B细胞表面受体结合，阻止B细胞异常分化和成熟，有效减轻机体的病理性免疫反应。目前在中国已获 批治疗重症肌无力(MG)、系统性红斑狼疮(SLE)和类风湿关节 ...

Core Insights - Hengdian Group's pharmaceutical arm Apeloa is leveraging Flow Chemistry to enhance sustainability in the pharmaceutical industry [1][2] - Apeloa has invested over USD 20 million in its flow chemistry platform over the past decade, emphasizing energy efficiency and reduced emissions [2] - The flow chemistry market is projected to grow at a 10% CAGR, reaching USD 2.9 billion by 2028, driven by regulatory support and scientific advancements [4] Group 1: Flow Chemistry Advantages - Flow chemistry allows for continuous chemical reactions, improving process safety and sustainability compared to traditional batch processing [3][6] - The method utilizes compact tubular reactors, providing better control over temperature, pressure, and time, resulting in less waste and higher yields [6] - Apeloa's flow chemistry platform supports the entire drug development lifecycle, from early development to commercial manufacturing [9] Group 2: Technological Developments - Apeloa has refined its flow chemistry platform technologically and commercially over the last ten years, with expertise in various high-value reactions [7][8] - The company’s Boston site specializes in early-stage flow chemistry, while its Shanghai and Hengdian locations handle larger scale samples [7] - A recent white paper published by Apeloa showcases its capabilities in high-risk reactions, demonstrating significant improvements in yield and safety [8][10] Group 3: Specific Reaction Improvements - Azide and Hydrogenation processes have been optimized to achieve 10-minute cycle times compared to 12 hours in batch processing [10] - Nitration with Acetyle Nitrate has shown an 80% yield in just 3 minutes, significantly faster than the traditional method [10] - Fluorination processes can handle a capacity of 12,000 tons/year with yields exceeding 90%, surpassing commercial standards [10]

Group 1 - A-share market sees a decline in several innovative drug concept stocks, with Yuekang Pharmaceutical dropping over 10% [1] - Guangshengtang falls by 8%, while Lifang Pharmaceutical and Haishike decrease by over 7% [1] - Saili Medical declines by over 6%, and Huiyu Pharmaceutical drops by over 5% [1] - Jingxin Pharmaceutical experiences a decline of over 4%, with Shutaishen, Haiteshengwu, and Xinlitai all falling by over 3% [1]

同仁堂科技披露的半年业绩显示，在其产品矩阵中，六味地黄丸领衔的泌尿补肾大品种集群表现亮眼， 六味地黄丸系列产品销售收入较上年同期增长约47.99%。在其带动下，金匮肾气丸系列销售收入同比 增长19.55%，壮腰健肾丸系列、知柏地黄丸系列及归芍地黄丸系列等产品的销售收入均较上年同期实 现双位数的增长。 围绕六味地黄丸、金匮肾气丸、壮腰健肾丸等品种，企业还依据产品特性制定差异化推广策略，布局微 博、抖音、小红书等深受年轻用户喜爱的平台，通过"线上+线下"联动营销，实现了市场占有率大幅度 提升。 今年下半年，同仁堂科技将持续强化品种培育，精准施策大品种集群矩阵建设，通过核心单品精准卡 位、渠道精细化建设，驱动业绩高质量增长。 而同仁堂"配方独特、选料上乘、工艺精湛、疗效显著"的制药特色则这一品种提供了有力支撑，企业将 药材鉴别、炮制、制药环节中的多项"非遗"技艺与现代工艺相结合，开发了水蜜丸、大蜜丸、软胶囊、 浓缩丸等剂型，满足不同群体、不同场景的用药需求。 同仁堂科技旗下六味地黄丸领衔的泌尿补肾大品种集群，还拥有知柏地黄丸、杞菊地黄丸、归芍地黄 丸、金匮肾气丸等众多明星产品，能够针对肾阴虚火旺、肝肾阴虚、肾阳虚等 ...

Summary of Radiopharm Theranostics (RADX) Update / Briefing August 26, 2025 Company and Industry Overview - **Company**: Radiopharm Theranostics (RADX) - **Industry**: Oncology, specifically focusing on prostate cancer treatment and radiopharmaceutical therapies Key Points and Arguments 1. **Prostate Cancer Treatment Landscape**: The treatment of prostate cancer has evolved significantly, moving from traditional methods like surgery and chemotherapy to incorporating genetics, molecular imaging, and targeted therapies, including immunotherapy and radiopharmaceuticals [11][12][30] 2. **B7-H3 as a Target**: B7-H3 is highlighted as a promising new target for prostate cancer treatment, being highly expressed in various tumors, including 93% of castrate-resistant prostate cancer cases. This makes it a viable alternative to PSMA-targeted therapies, especially in cases where PSMA expression is low [39][41][43] 3. **Need for New Therapies**: There is a critical need for more effective therapies for metastatic castration-resistant prostate cancer, as current treatments often provide limited survival benefits [18][30] 4. **NCCN Guidelines**: The National Comprehensive Cancer Network (NCCN) guidelines are discussed, emphasizing the importance of treatment sequencing and the variety of options available based on prior therapies [19][20] 5. **Theranostics Concept**: The concept of theranostics is introduced, where ligands are designed to bind to specific cancer cell targets, allowing for both diagnosis and treatment using radiopharmaceuticals [24][25] 6. **Clinical Trials and FDA Approvals**: The presentation mentions several clinical trials demonstrating survival benefits from new therapies, including the FDA approval of Plavicto (lutetium-177) for prostate cancer treatment [27][28][51] 7. **BetaBART Development**: The development of BetaBART, a humanized monoclonal antibody targeting the four Ig isoform of B7-H3, is presented as a novel approach in radioimmunotherapy, with plans for a Phase 1 trial in 2025 [51][66] 8. **Competitive Landscape**: The competitive landscape for B7-H3 targeting is discussed, noting that while there are other modalities like ADCs and CAR T-cell therapies, the unique properties of BetaBART provide a competitive advantage [75][78][87] 9. **Immunological Memory**: Evidence of secondary immune memory from prior treatments suggests that BetaBART may not only target tumors but also enhance the immune response against them [64][66] 10. **Market Potential**: The potential market for B7-H3 targeting therapies is significant, with opportunities extending beyond prostate cancer to other solid tumors [46][51] Other Important but Overlooked Content 1. **Challenges with Current Therapies**: The limitations of existing therapies, including the need for better options post-Plavicto treatment, are emphasized, highlighting the urgency for innovation in this space [30][102] 2. **Mechanism of Action**: The mechanism of action for BetaBART is discussed, focusing on its ability to selectively target the four Ig isoform of B7-H3 while minimizing off-target effects and toxicity [49][66] 3. **Future Directions**: The discussion includes the need for randomized control groups in future trials to better assess the efficacy of new treatments [31] This summary encapsulates the critical insights from the briefing, focusing on the advancements in prostate cancer treatment, the significance of B7-H3 as a target, and the innovative approaches being developed by Radiopharm Theranostics.

26 August 2025 | 3:37PM CST Zhejiang Huahai Pharmaceutical (600521.SS): Earnings review: 1H25 results mostly in line; TP up to Rmb15 to reflect positive pipeline Huahai released its 1H25 results on Aug 25, 2025. Both its revenue (Rmb4,516mn, -12% yoy) and net profits (Rmb409mn, -45% yoy) were mostly in-line with GSe (Rmb4,748mn/398mn, respectively). We are positive on the company's pipeline progress (which all belong to the company's subsidiary, Huaota Biotech; see the company's latest pipeline in Exhibit 1 ...

证券代码： 301507 证券简称：民生健康 杭州民生健康药业股份有限公司 投资者关系活动记录表 编号：2025-009 投资者关系活动 类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 ☑ 其他 （业绩交流会） 参与单位名称及 人员姓名 参与单位及人员详见附件 时间 2025 年 8 月 26 日 (周二) 上午 9:30-10:30 地点 公司会议室 上市公司接待人 员姓名 财务总监 朱文君 董事会秘书 陈稳竹 证券事务代表 鲍蔚霞 投资者关系活动 主要内容介绍 一、公司介绍环节 财务总监通过关键财务数据和核心财务指标等信息，详细介 绍了公司在上半年所取得的业绩表现及整体经营状况。 二、调研问答环节 1、问：公司主力维生素矿物质类产品 25H1 实现收入 4.26 亿元，收入占比 92.15%，同比增长 9.84%。其增长的逻辑是什 么，在未来是否能够持续保持稳定的收入增长？对于后续提升净 利率的思路和策略，公司有何考量？ 答：25H1 公司主力产品维矿系列保持稳健增长，其中主力 大单品 21 金维他多维元素片在线下渠道保持销售数量份额和销 ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.Novo Nordisk (NVO -1.90%) has risen to fame and prominence with its twin drugs Wegovy and Ozempic, with the former being particularly hot since it's approved for weight loss. However, on Tuesday a powerful rival to the company reported positive top-line results for a drug that could provide very stiff competition to the Danish pharmaceutical's top medication.Investors didn't react happily to thi ...

For personal use only Investor presentation 27 August 2025 IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES P aa g e� 1 1 Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties . Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to be correct . Actual results could differ materially from those anticip ...